Key result
GP IIb/IIIa inhibitors restore coronary flow in 100% of acute stent thrombosis cases precluding PCI.
Why the study?
Does GP IIb/IIIa platelet receptor inhibitor improve coronary blood flow in patients with acute stent thrombosis and technically impossible percutaneous intervention?
Does GP IIb/IIIa platelet receptor inhibitor improve coronary blood flow in patients with acute stent thrombosis and technically impossible percutaneous intervention?
GP IIb/IIIa inhibitors may serve as an effective salvage therapy for acute stent thrombosis when repeat percutaneous coronary intervention is technically impossible.
May offer salvage option when PCI impossible in acute stent thrombosis; hypothesis-generating from Level 5 evidence.
Over the past 10—15 years, more than ten blockers of GP IIb/IIIa platelet receptors have been created. Mechanism of their action is blockade of membrane glycoprotein receptors of platelets that leads to suppression of common final pathway of aggregation. GP IIb/IIIa platelet receptor inhibitor eliminated coronary artery thrombosis according to coronary angiography and allowed restoration of coronary blood flow in “no-reflow” phenomenon in 100% of cases. The authors used GP IIb/IIIa inhibitor of platelet receptors for the treatment of acute stent thrombosis with technical impossibility of repeated percutaneous coronary intervention with positive effect.
No takes yet. Share an insight, caveat, or question.
Tarasov et al. (2026) studied this question. GP IIb/IIIa platelet receptor inhibitor restored coronary blood flow and eliminated thrombosis in 100% of acute stent thrombosis cases where percutaneous intervention was impossible.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: